Last reviewed · How we verify
JW0201
JW0201 is a small molecule that targets the SGLT2 receptor.
JW0201 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | JW0201 |
|---|---|
| Also known as | JW0201+C2022+C2204 |
| Sponsor | JW Pharmaceutical |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, JW0201 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of JW0201's interaction with SGLT2 are not well-documented.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus (PHASE3)
- To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM (PHASE3)
- To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers (PHASE1)
- To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JW0201 CI brief — competitive landscape report
- JW0201 updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI